Covidien Launches EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System in Australia and New Zealand
Stent Delivery System Offers Controlled, One-Handed Delivery, Greater Accuracy and Ease of Use
DUBLIN, Ireland--(BUSINESS WIRE)--Covidien plc today announced the launch of its EverFlex™ Self-expanding Peripheral Stent with Entrust™ Delivery System in Australia and New Zealand. The latest version of the EverFlex stent features the new Entrust Delivery System, which enables physicians to consistently place stents with accuracy, while providing the ease of a one-handed device.
“Our Entrust Delivery System allows for one-handed delivery of the EverFlex stent for treating patients with PAD”
“It is impressive to see the existing EverFlex stent now available on an easy to use, low profile, triaxial designed delivery system,” said Michael Denton, associate professor, Epworth Hospital, Richmond. “With a lower profile, the puncture site is smaller, possibly resulting in fewer access site complications and faster ambulatory rates.”
The Entrust Delivery System deploys the EverFlex stent, which is used to re-open narrowed (stenotic) regions of the superficial femoral and proximal popliteal arteries that supply blood to the legs. Narrowing of these arteries is associated with a condition known as peripheral arterial disease (PAD), where plaque builds along lining of the arteries, blocking blood flow to the legs. The 36-month results from the DURABILITY II study demonstrate that even in long, complex lesions, the EverFlex stent is able to sustain patency and durability.1 Furthermore, with the Entrust Delivery System, physicians can deploy all sizes, up to 150 millimeter lengths, of the Covidien EverFlex stent on a low 5 F profile with preserved radial force.
“Our Entrust Delivery System allows for one-handed delivery of the EverFlex stent for treating patients with PAD,” said Mark A. Turco, MD, chief medical officer, Vascular Therapies, Covidien. “The design of the system is based on extensive physician feedback and procedural observation, and should allow for better performance during stent deployment.”
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien develops, manufactures and sells a diverse range of industry-leading medical device and supply products. With 2013 revenue of $10.2 billion, Covidien has more than 38,000 employees worldwide in more than 70 countries, and its products are sold in over 150 countries. Please visit www.covidien.com to learn more about our business.